C108P: Rovalpituzumab Biosimilar, DLL3 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The research grade rovalpituzumab biosimilar specifically binds to the human DLL3 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rovalpituzumab.